

Case Series of Neuropathy with Ophthalmoplegia and Dysarthria

**Tekalign Burka, MD, Mamatha Pasnoor, MD, Omar Jawdat, MD, Melanie
Glenn, MD, Duaa Jabari, MD, Mazen M Dimachkie, MD**

**Carrell-Krusen Neuromuscular Symposium
February 23, 2018**

Background: Mitochondrial diseases

- **Disrupt fundamental cellular energy process resulting in multisystem diseases**
- **Brain, nerves and muscles are frequently involved with variable severity**
- **Caused by mutations in nuclear or mitochondrial DNA**
- **Phenotypic and genotypic variability**
 - **MERRF, MELAS, SANDO, MNGIE, axonal CMT2 etc**

Objective

- **Describe clinical characteristic and diagnostic features of patients with sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO) at the KUMC**

Method

- **Retrospective chart review of patients with clinical diagnosis of SANDO at the University of Kansas Medical Center**
- **IRB submission and approval at the University of Kansas Medical Center with exempt status**

Results – Demographics

Participants	n = 5
Gender (M/F)	1/4
Median age at presentation (years)	40
Positive Family History	4/5 (3 siblings)
Muscle biopsy	3
Genetic confirmation	1

Results – Clinical data

PATIENTS (n=5)	1	2a	2b	2c	3
Age of onset	40	45	45	32	28
Foot numbness onset	51	45	45	33	28
Ocular onset	40, P → D	54, D	55, D	43, D	30, D
Ataxia onset	51	55	55	32	30
Dysarthria onset	52	No	No	No	52
P-ptosis; D-diplopia; 2a, 2b, and 2c-siblings					

Results – Diagnostic data

PATIENTS (n=5)	1	2a	2b	2c	3
Electrophysiology	Severe axonal, S>M, Irritative myopathy	N.D.	Moderate axonal, S>M, Irritative myopathy	N.D.	Mild axonal, S
Muscle biopsy	>10% COX- and SDH+	>30% COX- and SDH+	N.D.	N.D.	Non specific myopathy, Mild denervation atrophy
POLG mutation	N.D.	N.D.	N.D.	No mutation detected	2 VUS likely pathogenic (compound heterozygote)

M-motor, S-sensory, N.D-not done, 2a, 2b, and 2-siblings, VUS-variants of unknown significant

Literature review: SANDO

- **Autosomal recessive systemic disorder with progressive clinical triad of sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO)**
 - **Initial sign is neuropathy**
 - Large and small fiber sensory loss
 - Variable motor involvement
 - **Later signs are ptosis, ophthalmoplegia**
 - May also have dysarthria and facial weakness
- **Mutation of the gene encoding mitochondrial DNA polymerase gamma enzyme (POLG1)**
 - **Mitochondrial DNA deletion**

Literature review: Diagnostic findings

- **Electrophysiology**
 - Axonal neuropathy with reduced or absent SNAP
 - Distal denervation and occasional proximal myopathy
- **Muscle pathology**
 - Ragged red fibers
 - COX- and SDH+ fibers
- **Genetic testing**
 - Multiple POLG mutation ~ 78%
 - PEO1 (twinkle helicase)

Discussions

- **“SANDO syndrome in a cohort of 107 patients with CPEO and mitochondrial DNA deletions”**
 - Retrospective analysis
 - Identified a total of 11 patients with SANDO
- **Conclusions**
 - Most patients initially presented with ataxia
 - CPEO followed in the first decade of neuropathy
 - Vast majority caused by POLG mutations but other nuclear genes include PEO1

Discussions

- **In our case series, the most common initial presenting symptom was foot numbness**
- **Most patients had sensory ataxia and ophthalmoparesis within a decade from symptom onset**
- **Dysarthria was delayed (12-24yrs.) present in the minority of cases**

Discussions

Presenting symptoms	Present study n = 5	CPEO cohort n = 11
Initial foot numbness	3 (60%)	Not reported
Initial Ataxia	1 (20%)	8 (73%)
Foot numbness/ataxia	5 (100%)	11 (100%)
Initial PEO	1 (20%)	3 (27%)
PEO	5 (100%)	10 (91%)
Initial dysarthria/dysphasia	0	1 (9%)
Dysarthria/dysphasia	2 (40%)	11 (100%)
PEO-progressive external ophthalmoplegia		

Discussions

Diagnostic testing	Present study n = 5	CPEO cohort n = 11
Axonal sensory neuropathy	3/3 S>M	11 (100%) S>M
Muscle biopsy	2/3 >10% COX- and SDH+ >30% COX- and SDH+	9/11 COX- [1.3%-25%] Median 3.1%
Genetic testing (POLG)	1/2 *2 VUS likely pathogenic (compound heterozygote mutations seen in patients with SANDO)	6/10 *The 2 POLG- patients were PEO1+
S-sensory, M-motor, VUS-variants of unknown significance		

Conclusions

- **Foot numbness followed by ataxia and ophthalmoparesis is the presenting symptom in majority of SANDO cases**
- **Dysarthria was the least consistent finding of the triad and was delayed**
 - SANDO seem to be the most frequent phenotype
- **Direct POLG mutation screening can avoid costly invasive muscle biopsy**
- **May benefit from additional PEO1 screening**

Thanks you

- **Questions?**



Reference

1. Cassereau J Codron P Funalot B . Inherited peripheral neuropathies due to mitochondrial disorders . *Rev Neurol (Paris)* 2014 ; 170 : 366 – 74 .
2. Weiss MD, Saneto RP. Sensory ataxic neuropathy with dysarthria and ophthalmoparesis (SANDO) in late life due to compound heterozygous *POLG* mutations, *Muscle Nerve* , 2010, vol. 41 (pg. 882-5)
3. Hanish F, *et al.* *J Neurol Neurosurg psychiatry* 2015; 86 630-634. doi: 10.1136/jnnp-2013-306748
4. Fadic, R., Russell, J. A., Vedanarayanan, V. V., Lehar, M., Kuncl, R. W., Johns, D. R. Sensory ataxic neuropathy as the presenting feature of a novel mitochondrial disease. *Neurology* 49: 239-245, 1997.